Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
192
resultados
Última actualización
15/06/2025 [06:53:00]
Resultados 125 a 150 de 192
Resumen de: AU2023391361A1
Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.
Resumen de: AU2023272087A1
Described herein are particles including a protein and an active agent such as a particle comprising α-lactalbumin and tryptophan. Also described herein are methods of making and using particles that include a protein and an active agent.
Resumen de: WO2023223307A1
The invention provides multifunctional system for the synchronized delivery of distinct immunoglobulins, in particular antibodies and antibody fragments to specific cancerous cells and tissues located outside of the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first immunoglobulin; through a second polymeric linker to a second immunoglobulin; through a third polymeric linker to a penetration enhancing moiety; and to a fourth, monofunctional capping linker or spacer. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.
Resumen de: US2025064972A1
The present invention provides a conjugate comprising: (a) a cancer-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, (b) an inner shell comprising oligomeric (−)-epigallocatechin gallate (OEGCG), and optionally (c) a cancer-treating molecule encapsulated in the inner shell. In one embodiment, the nanoparticle composition has at least 70% of the nanoparticles with a diameter between 20-500 nm or 50-300 nm, and one single major peak in the size distribution. The present invention further provides a method for treating cancer by administering an effective amount of the present nanoparticle composition to a subject. The cancer-targeting ligand targets the tumor and delivers active ingredients to tumor for treating cancer.
Resumen de: AU2023378958A1
The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.
Resumen de: WO2025117906A1
Described herein are microfluidic approaches for the assembly of nanoparticles manufactured from isolated red blood cell (RBC) lipids and components. The engineered nanoparticles (e.g., vesicles) can be used to encapsulate cargo, including active agents such as proteins, nucleic acids (e.g., RNA), and other classes of therapeutic agents. Optionally, the vesicles can be further functionalized with targeting agents.
Resumen de: WO2025117832A1
Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.
Resumen de: WO2025117815A1
Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
Resumen de: WO2025116441A1
The present disclosure relates to a pharmaceutical composition for preventing or treating osteoarthritis. The pharmaceutical composition for preventing or treating osteoarthritis according to the present disclosure is not only highly stable, thereby exhibiting excellent therapeutic effects, but is also expected to be a disease-modifying osteoarthritis drug (DMOAD)-class therapeutic agent that can prevent and preemptively treat osteoarthritis by overcoming the limitations of cell therapeutic agents through the use of mRNA.
Resumen de: WO2025117969A1
The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.
Resumen de: WO2025114909A1
Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.
Resumen de: WO2025117817A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs), the LNP comprising at least two selective organ targeting (SORT) lipids and/or at least six lipids. Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: WO2025117822A1
Described herein are self-assembled peptides and hydrogels comprising self-assembled peptides and glucose. Exemplary hydrogels comprising self-assembled peptides and glucose may be used to encapsulate glucagon and/or a glucagon analogue. Hydrogels with glucagon and/or a glucagon analogue encapsulated therein may be used to treat hypoglycemia and related disorders in subjects in need thereof.
Resumen de: WO2025117816A1
Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.
Resumen de: WO2025117732A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
Resumen de: WO2025116177A1
The present invention relates to a pharmaceutical composition comprising mesenchymal stem cells overexpressing interleukin-10 (IL-10), poly-L-lactic acid particles, and hydrogel, wherein the composition has remarkably excellent adhesion and proliferation abilities of stem cells with a medicinal effect on degenerative arthritis, thereby exhibiting an excellent medicinal effect on degenerative arthritis.
Resumen de: WO2025116961A1
The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.
Resumen de: WO2025114612A1
Hybrid particles comprising a cross-linked polysaccharide matrix and metal oxide nanoparticles The invention relates to a method of manufacturing hybrid particles comprising a matrix of cross-linked polysaccharide and metal oxide nanoparticles embedded therein. It has been found that hybrid particles with low polydispersity and a high load of metal oxide nanoparticles could be obtained when non-coated metal oxide nanoparticles are used. Aggregation of the non-coated metal oxide nanoparticles could be controlled to achieve said polydispersity and load. The hybrid particles of the invention, when the metal oxide is a magnetic and photothermal metal oxide, could act on the thrombosis via a combination of thermal and mechanical action, through light and magnetic stimulation, and would be targeted to the occluded vessel by an external permanent magnet.
Resumen de: WO2025114613A1
Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.
Resumen de: WO2025116522A1
The present invention relates to silica-based nanoparticles for sustained release of a hydrophilic drug and a manufacturing method thereof, the nanoparticles comprising: silica-based hollow nanoparticles comprising a hollow core layer and a silica matrix shell layer infiltrated with metal; and a hydrophilic drug supported by the hollow nanoparticles.
Resumen de: WO2024026444A1
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.
Resumen de: WO2024026029A2
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Resumen de: EP4563142A1
The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.
Resumen de: EP4563528A1
The present invention relates to a silica mesoporous nanoparticle comprising a covalently bound protein G' or protein A, the composition comprising said nanoparticle, the use thereof for capturing, purifying, eliminating and/or isolating immunoglobulins, preferably IgG, as well as a method for purifying an immunoglobulin, methods for pre-treating samples in order to subsequently diagnose allergies, infections and/or autoimmune diseases in a patient, and said diagnostic methods.
Nº publicación: EP4561532A2 04/06/2025
Solicitante:
UNIV GEORGIA STATE RES FOUND [US]
Georgia State University Research Foundation, Inc
Resumen de: WO2024030865A2
Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, 1 to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.
BOPI
Sede Electrónica
